Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$2.1b

Supernus Pharmaceuticals Future Growth

Future criteria checks 3/6

Supernus Pharmaceuticals is forecast to grow earnings and revenue by 36.2% and 5.9% per annum respectively while EPS is expected to grow by 34.8% per annum.

Key information

36.2%

Earnings growth rate

34.8%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate5.9%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Dec 2024

Recent future growth updates

Recent updates

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Earnings and Revenue Growth Forecasts

NasdaqGM:SUPN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202667722113N/A4
12/31/2025621-52902014
12/31/2024642531402484
9/30/202465260172173N/A
6/30/20246305154155N/A
3/31/2024597-16100100N/A
12/31/20236081111111N/A
9/30/2023611269394N/A
6/30/2023634437172N/A
3/31/202366852162162N/A
12/31/202266761116117N/A
9/30/202265938138138N/A
6/30/202263057120120N/A
3/31/2022601739495N/A
12/31/202158053125127N/A
9/30/202156482108110N/A
6/30/2021571100117120N/A
3/31/2021556111163166N/A
12/31/2020520127135138N/A
9/30/2020477129145150N/A
6/30/2020424118177182N/A
3/31/2020402116114119N/A
12/31/2019393113142143N/A
9/30/2019408106131132N/A
6/30/2019409105156157N/A
3/31/2019404103134135N/A
12/31/2018409111128129N/A
9/30/201838199131132N/A
6/30/201835987N/A109N/A
3/31/201833573N/A128N/A
12/31/201730257N/A115N/A
9/30/201727658N/A103N/A
6/30/2017253104N/A92N/A
3/31/201722897N/A83N/A
12/31/201621591N/A67N/A
9/30/201619684N/A64N/A
6/30/201617926N/A35N/A
3/31/201616318N/A32N/A
12/31/201514714N/A35N/A
9/30/201513511N/A18N/A
6/30/20151185N/A14N/A
3/31/20151125N/A-6N/A
12/31/201493-11N/A-24N/A
9/30/201472-37N/A-40N/A
6/30/201450-59N/A-51N/A
3/31/201421-89N/A-60N/A
12/31/201312-92N/A-58N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUPN's forecast earnings growth (36.2% per year) is above the savings rate (2.6%).

Earnings vs Market: SUPN's earnings (36.2% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: SUPN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SUPN's revenue (5.9% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: SUPN's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 09:34
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
David BuckB. Riley Securities, Inc.
John TannerCantor Fitzgerald & Co.